Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2013

Open Access 01-06-2013 | Case Report

Postoperative Pyoderma Gangrenosum in Association with Renal Cell Carcinoma and Chronic Lymphocytic Leukemia

Authors: Caius Solovan, Robert Smiszek, Claudia Wickenhauser, Elena Chiticariu

Published in: Infectious Diseases and Therapy | Issue 1/2013

Login to get access

Abstract

Introduction

Pyoderma gangrenosum (PG) is a rare sterile neutrophilic dermatosis characterized by painful recurrent ulcerations. It is frequently associated with inflammatory bowel disease, rheumatoid arthritis, or malignancies. PG is a diagnosis of exclusion, and it is based on clinical presentation, histology, history of an underlying disease, and exclusion of other causes of ulceration.

Case Report

The authors report a 62-year-old male who developed a nonhealing ulcer at the site of incision following nephrectomy for renal cell carcinoma. Past medical history included chronic lymphocytic leukemia treated with rituximab. Histology of the skin lesion showed a phlegmonous nonspecific inflammation without being able to differentiate between a necrotizing wound infection and PG. The patient’s condition was initially diagnosed as an infectious process and treated accordingly. After unsuccessful results with systemic antibiotics, high-dose corticosteroids induced prompt healing of the wound. On these bases, the diagnosis of postoperative PG within chronic lymphocytic leukemia and renal cell carcinoma was made.

Conclusion

Faced with postoperative necrotizing ulceration resistant to correctly administered antibiotics, PG must be considered. In such condition, the diagnosis must not be guided primarily by histology and early advice of a dermatologist is recommended.
Literature
2.
go back to reference Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 2013 (Epub ahead of print). Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 2013 (Epub ahead of print).
3.
go back to reference Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162:100–7.PubMedCrossRef Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162:100–7.PubMedCrossRef
4.
go back to reference Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol. 1930; 22:655–80. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol. 1930; 22:655–80.
5.
go back to reference Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008–17.PubMedCrossRef Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008–17.PubMedCrossRef
6.
go back to reference Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409.PubMedCrossRef Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409.PubMedCrossRef
7.
go back to reference Marzano AV, Tourlaki A, Alessi E, et al. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol. 2008;33:156–9.PubMedCrossRef Marzano AV, Tourlaki A, Alessi E, et al. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol. 2008;33:156–9.PubMedCrossRef
8.
go back to reference Lyon CC, Smith AJ, Beck MH, et al. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol. 2000;42:992–1002.PubMedCrossRef Lyon CC, Smith AJ, Beck MH, et al. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol. 2000;42:992–1002.PubMedCrossRef
9.
go back to reference Marzano AV, Ishak RS, Lazzari R, et al. Vulvar pyoderma gangrenosum with renal involvement. Eur J Dermatol. 2012;22:537–9.PubMed Marzano AV, Ishak RS, Lazzari R, et al. Vulvar pyoderma gangrenosum with renal involvement. Eur J Dermatol. 2012;22:537–9.PubMed
10.
go back to reference McAleer MA, Powell FC, Devaney D, et al. Infantile pyoderma gangrenosum. J Am Acad Dermatol. 2008;58:S23–8.PubMedCrossRef McAleer MA, Powell FC, Devaney D, et al. Infantile pyoderma gangrenosum. J Am Acad Dermatol. 2008;58:S23–8.PubMedCrossRef
11.
go back to reference Poiraud C, Gagey-Caron V, Barbarot S, et al. Cutaneous, mucosal and systemic pyoderma gangrenosum. Ann Dermatol Venereol. 2010;137:212–5.PubMedCrossRef Poiraud C, Gagey-Caron V, Barbarot S, et al. Cutaneous, mucosal and systemic pyoderma gangrenosum. Ann Dermatol Venereol. 2010;137:212–5.PubMedCrossRef
12.
go back to reference Cullen TS. A progressively enlarging ulcer of the abdominal wall involving the skin and fat, following drainage of an abdominal abscess apparently of appendiceal origin. Surg Gynecol Obstet. 1924;38:579–82. Cullen TS. A progressively enlarging ulcer of the abdominal wall involving the skin and fat, following drainage of an abdominal abscess apparently of appendiceal origin. Surg Gynecol Obstet. 1924;38:579–82.
13.
go back to reference Schöfer H, Baur SJ. Successful treatment of postoperative pyoderma gangrenosum with cyclosporin. Eur Acad Dermatol Venereol. 2002;16:148–51.CrossRef Schöfer H, Baur SJ. Successful treatment of postoperative pyoderma gangrenosum with cyclosporin. Eur Acad Dermatol Venereol. 2002;16:148–51.CrossRef
14.
go back to reference Ouazzani A, Berthe JV, de Fontaine S. Post-surgical pyoderma gangrenosum: a clinical entity. Acta Chir Belg. 2007;107:424–8.PubMed Ouazzani A, Berthe JV, de Fontaine S. Post-surgical pyoderma gangrenosum: a clinical entity. Acta Chir Belg. 2007;107:424–8.PubMed
15.
go back to reference Gooding JM, Kinney TB, Oglevie SB, et al. Pyoderma gangrenosum twice complicating percutaneous intervention in a single patient. AJR Am J Roentgenol. 1999;172:1352–4.PubMedCrossRef Gooding JM, Kinney TB, Oglevie SB, et al. Pyoderma gangrenosum twice complicating percutaneous intervention in a single patient. AJR Am J Roentgenol. 1999;172:1352–4.PubMedCrossRef
17.
go back to reference Ho K, Otridge BW, Vanderberg E, et al. Pyoderma gangrenosum, polycythemia rubravera, and the development of leukemia. J Am Acad Dermatol. 1992;27:804–8.PubMedCrossRef Ho K, Otridge BW, Vanderberg E, et al. Pyoderma gangrenosum, polycythemia rubravera, and the development of leukemia. J Am Acad Dermatol. 1992;27:804–8.PubMedCrossRef
18.
go back to reference Swale VJ, Saha M, Kapur N, et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol. 2005;30:134–6.PubMedCrossRef Swale VJ, Saha M, Kapur N, et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol. 2005;30:134–6.PubMedCrossRef
19.
go back to reference Walsh M, Leonard N, Bell H. Superficial granulomatous pyoderma of the vulva in a patient receiving maintenance rituximab (MabThera) for lymphoma. J Low Genit Tract Dis. 2011;15:158–60.PubMedCrossRef Walsh M, Leonard N, Bell H. Superficial granulomatous pyoderma of the vulva in a patient receiving maintenance rituximab (MabThera) for lymphoma. J Low Genit Tract Dis. 2011;15:158–60.PubMedCrossRef
20.
go back to reference Bryan CS. Fatal pyoderma gangrenosum with pathergy after coronary artery bypass grafting. Tex Heart Inst J. 2012;39:894–7.PubMed Bryan CS. Fatal pyoderma gangrenosum with pathergy after coronary artery bypass grafting. Tex Heart Inst J. 2012;39:894–7.PubMed
21.
go back to reference Ryu J, Naik H, Yang FC, Winterfield L. Pyoderma gangrenosum presenting with leukemoid reaction: a report of 2 cases. Arch Dermatol. 2010;146:568–9.PubMedCrossRef Ryu J, Naik H, Yang FC, Winterfield L. Pyoderma gangrenosum presenting with leukemoid reaction: a report of 2 cases. Arch Dermatol. 2010;146:568–9.PubMedCrossRef
23.
go back to reference Thwaini A, Khan A, Malik A, et al. Fournier’s gangrene and its emergency management. Postgrad Med J. 2006;82:516–9.PubMedCrossRef Thwaini A, Khan A, Malik A, et al. Fournier’s gangrene and its emergency management. Postgrad Med J. 2006;82:516–9.PubMedCrossRef
24.
go back to reference Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. Am J Surg. 2000;179:361–6.PubMedCrossRef Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. Am J Surg. 2000;179:361–6.PubMedCrossRef
25.
go back to reference Callen JP, Jackson JM. Pyodermagangrenosum: an update. Rheum Dis Clin N Am. 2007;33:787–802.CrossRef Callen JP, Jackson JM. Pyodermagangrenosum: an update. Rheum Dis Clin N Am. 2007;33:787–802.CrossRef
Metadata
Title
Postoperative Pyoderma Gangrenosum in Association with Renal Cell Carcinoma and Chronic Lymphocytic Leukemia
Authors
Caius Solovan
Robert Smiszek
Claudia Wickenhauser
Elena Chiticariu
Publication date
01-06-2013
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2013
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-013-0008-4

Other articles of this Issue 1/2013

Infectious Diseases and Therapy 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine